1
Results: There were no significant differences between the groups in clinical outcome.
2
However, the gray matter volumetric enlargements were not associated with clinical outcome.
3
Preservation of pancreatic tissue can be achieved with a good clinical outcome.
4
Adverse effect profiles and clinical outcome, in the cohorts are largely similar.
5
The type of AMI did not influence risk assessment and clinical outcome.
6
Patients with ALK non-variant 1 had better clinical outcome on first-line chemotherapy.
7
The three-month immunologic response is a reliable predictor of long-term clinical outcome.
8
All clinical outcome scores were significantly improved and no significant complication occurred.
9
The clinical outcome after the treatment was evaluated for each mutation status.
10
In the lumbar group, status of arthrodesis correlated closely with clinical outcome.
11
An improvement in the clinical outcome was also observed compared with controls.
12
Renal dysfunction does not alter the effects of nifedipine on clinical outcome.
13
Prognostic factors of clinical outcome were assessed by univariate and multivariate analysis.
14
Histologic assessment was then correlated with lymph node status and clinical outcome.
15
Non-inferiority of telerehabilitation could not be claimed for any clinical outcome measure.
16
No correlation between clinical outcome and MIC was observed for amphotericin B.
